IFN-alpha and amantadine for treating hepatitis C

• US 20030031647A1
• Filed: 09/06/2002
• Published: 02/13/2003
• Est. Priority Date: 09/18/1997
• Status: Abandoned Application

• Current Assignee: Friederike Zahm
• Original Assignee: Friederike Zahm
• Inventors: Zahm, Friederike
• Application Number:
  US10/236,268
• Publication Number:
  US 20030031647A1
• Time in Patent Office: Days
• US Class Current: 424/85.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/212 IFN-alpha
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals

Abstract

The present invention provides a method for treating chronic hepatitis C infections in patients in need of such treatment comprising administering an amount of IFN-α in association with an amount of amantadine effective to treat hepatitis C. In accordance with the invention, IFN-α and amantadine are administered at the same time or sequentially. The present invention also provides a kit for treating a hepatitis C infection containing IFN-α and amantadine in suitable dosage forms for administering the combination therapy.

Claims

1. A method of treating hepatitis C in a patient in need of such treatment comprising-administering to said patient an amount of a first hepatitis C active ingredient in association with an amount of a second hepatitis C active ingredient wherein said first ingredient is an IFN-α

or a pegylated IFN-α and

said second ingredient is amantadine or a pharmaceutically acceptable salt thereof, said first and second ingredients being administered in combined amounts which synergistically enhance said treatment provided by administering each ingredient separately.

2. The method of claim 1, wherein the amount of the first ingredient is administered parenterally and the amount of the second ingredient is administered orally.

3. The method of claim 2, wherein the administration of the first ingredient is followed by administration of the second ingredient.

4. The method of claim 2, wherein the administration of the first ingredient is preceded by administration of the second ingredient.

5. The method of claim 2, wherein the amount of the first ingredient administered is from about 1 million IU to about 6 million IU at least once weekly.

6. The method of claim 5, wherein the amount of the first ingredient is administered from one to three times per week.

7. The method of claim 5, wherein the first ingredient is IFN-α

2A.

8. The method of claim 5, wherein the first ingredient is PEG-IFN-α

2A.

9. The method of claim 2, wherein the amount of the second ingredient administered is from about 1.5 mg/kg to about 6.5 mg/kg of body weight at least once weekly.

10. The method of claim 9, wherein the amount of the second 10 ingredient administered is from about 3.0 mg/kg to about 4.0 mg/kg of body weight at least once weekly.

22. The method of claim 8, wherein the PEG-IFN-α

2A is a conjugate of the formula;

23. The method of claim 22, wherein R and R′

are methyl.

24. The method of claim 22, wherein n and n′

are either 420 or 520 with the proviso that n and n′

are not the same.

11. A method of treating hepatitis C in a patient in need of such treatment comprising administering to said patient an amount of a first is hepatitis C active ingredient in association with an amount of a second hepatitis C active ingredient wherein said first ingredient is an IFN-α

or a pegylated IFN-α and

said second ingredient is amantadine or a pharmaceutically acceptable salt thereof, with the first ingredient being administered parenterally at from about 1 million IU to about 6 million IU at least once weekly and said second ingredient being administered orally at a dose from about 1.5 mg/kg to about 6.5 mg/kg of body weight at least once weekly.

12. The method of claim 11, wherein the first ingredient is IFN-α

2A.

13. The method of claim 11, wherein the first ingredient is PEG-IFN-α

2A.

14. The method of claim 11, wherein the first ingredient and second ingredient are each administered from one to three times weekly.

15. The method of claim 11, wherein the amount of the first ingredient administered is about 3 million IU to about 4 million IU one to three times weekly and the amount of the second ingredient administered is about 3.0 mg/kg to about 4.0 mg/kg of body weight one to three times weekly.

25. The method of claim 13, wherein the PEG-IFN-α

2A is a conjugate of the formula;

26. The method of claim 25, wherein R and R′

are methyl.

27. The method of claim 25, wherein n and n′

are either 420 or 520 with the proviso that n and n′

are not the same.

16. A kit for treating a hepatitis C infection said kit comprising a first component which is an IFN-α

or a pegylated IFN-α

in an injectable solution, said solution having an amount of IFN-α

or PEG-IFN-α

sufficient to administer to a patient in single or multiple injectable dosages of from about 1 million to about 6 million IU of IFN-α

or PEG-IFN-α

per dose, and a second component which is amantadine or a pharmaceutically acceptable salt thereof in suitable oral unit dosage forms, said oral unit dosage forms containing from about 100 mg to about 400 mg of amantadine or a pharmaceutically acceptable salt thereof.

17. The kit of claim 16, wherein the IFN-α

is IFN-α

2A.

18. The kit of claim 16, wherein the IFN-α

is PEG-IFN-α

2A.

19. The kit of claim 16, wherein said first component is a vial or a series of vials containing said injectable solution, said injectable solution in said vial being an amount of IFN-α

or PEG-IFN-α

sufficient to provide a patient in a single administration of from about 3 million to about 4 million IU of IFN-α

or PEG-IFN-α

.

20. The kit of claim 16, wherein the second component includes amantadine or a pharmaceutically acceptable salt thereof in oral unit dosage forms wherein each of the oral unit dosage forms in said second component contain from about 200 mg to about 300 mg of amantadine or a pharmaceutically acceptable salt thereof.

21. The kit of claim 16, wherein said second component includes amantadine or a pharmaceutically acceptable salt thereof in oral unit dosage forms wherein the oral unit dosage forms in said second component are capsules or tablets.

28. The method of claim 18, wherein the PEG-IFN-α

2A is a conjugate of the formula;

29. The method of claim 28, wherein R and R′

are methyl.

30. The method of claim 28, wherein n and n′

are either 420 or 520 with the proviso that n and n′

are not the same.